Dendritic cells in atherosclerosis: integrating ontogeny, functional states, spatial organization, and therapeutic implications
- 1Yangtze University, First Affiliated Hospital of Yangtze University
- 2Yangtze University Health Science Center, Yangtze University
Abstract
Atherosclerosis arises from the interaction between lipid accumulation and sustained innate and adaptive immune activation, and residual cardiovascular risk despite intensive lipid-lowering therapy underscores the need to clarify vascular inflammatory mechanisms. Dendritic cells (DCs) link antigen sensing and presentation to T-cell regulation, but their roles in atherosclerosis remain incompletely resolved. This review synthesizes evidence on conventional type 1 and type 2 DCs, plasmacytoid DCs, and monocyte-derived DC-like cells using a lineage–state–location–validation framework that asks which cells are present, which functional programs they exhibit, where they are located, and what evidence supports the proposed function. Current evidence indicates that lineage defines functional potential but does not determine pathological activity; lipid loading, oxidative and metabolic stress, extracellular nucleic acids, cytokines, anatomical compartment, and disease stage can shift DCs toward inflammatory, regulatory, or dysfunctional states. Single-cell and spatial profiling have improved resolution of plaque-associated myeloid populations, but rare human DCs, overlap with macrophages and monocytes, cross-sectional sampling, and the inability of expression or proximity to establish causality remain important limitations. Therapeutic strategies should be distinguished as direct or DC-enriched delivery, state- or pathway-directed modulation, and indirect effects on DC function. Current interventions remain preclinical and generally lack sufficient cellular or state selectivity. Future work should prioritize reproducible human DC-state identification, lineage-resolved spatial and functional validation, established-disease models, and biomarkers of pathway activity and target engagement. No specific human DC state is yet clinically actionable.
Related
- Vascular Smooth Muscle Cell Plasticity in Atherosclerosis: From Macrophage-like Transdifferentiation to Therapeutic Targeting
- Vascular and Immune Cell Interactions in Atherosclerosis: Mechanisms, Plaque Destabilization, and Therapeutic Opportunities
- Atherosclerosis: From Pathogenesis to Therapeutic Interventions
- Single-cell T-cell landscape in atherosclerosis: implications for targeted therapy and beyond
- The role of interferon regulatory factors in atherosclerosis: from cell type-specific mechanisms to therapeutic strategies
BibTeX
@article{shao2026dendritic,
title = {{Dendritic cells in atherosclerosis: integrating ontogeny, functional states, spatial organization, and therapeutic implications}},
author = {Wei Shao and Yunxian Zhang and Huasong Luo and Jinbai Huang},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1968525},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1968525/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Dendritic cells in atherosclerosis: integrating ontogeny, functional states, spatial organization, and therapeutic implications
AU - Wei Shao
AU - Yunxian Zhang
AU - Huasong Luo
AU - Jinbai Huang
PY - 2026
DA - 2026/10/20
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1968525
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1968525/full
AB - Atherosclerosis arises from the interaction between lipid accumulation and sustained innate and adaptive immune activation, and residual cardiovascular risk despite intensive lipid-lowering therapy underscores the need to clarify vascular inflammatory mechanisms. Dendritic cells (DCs) link antigen sensing and presentation to T-cell regulation, but their roles in atherosclerosis remain incompletely resolved. This review synthesizes evidence on conventional type 1 and type 2 DCs, plasmacytoid DCs, and monocyte-derived DC-like cells using a lineage–state–location–validation framework that asks which cells are present, which functional programs they exhibit, where they are located, and what evidence supports the proposed function. Current evidence indicates that lineage defines functional potential but does not determine pathological activity; lipid loading, oxidative and metabolic stress, extracellular nucleic acids, cytokines, anatomical compartment, and disease stage can shift DCs toward inflammatory, regulatory, or dysfunctional states. Single-cell and spatial profiling have improved resolution of plaque-associated myeloid populations, but rare human DCs, overlap with macrophages and monocytes, cross-sectional sampling, and the inability of expression or proximity to establish causality remain important limitations. Therapeutic strategies should be distinguished as direct or DC-enriched delivery, state- or pathway-directed modulation, and indirect effects on DC function. Current interventions remain preclinical and generally lack sufficient cellular or state selectivity. Future work should prioritize reproducible human DC-state identification, lineage-resolved spatial and functional validation, established-disease models, and biomarkers of pathway activity and target engagement. No specific human DC state is yet clinically actionable.
SN - 1664-3224
ER -